Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: metabolic disorder therapeutics - Acquist Therapeutics

Next Previous
Drug Profile

Research programme: metabolic disorder therapeutics - Acquist Therapeutics

Alternative Names: RLBN 1001; RLBN 11127; RLBN 1133; RLBN 2020 series; RLBN 3010 series

Latest Information Update: 28 Aug 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Relburn Metabolomics
  • Developer Acquist Therapeutics
  • Class Antigouts; Hepatoprotectants; Small molecules; Uricosurics
  • Mechanism of Action SLC22A12 protein inhibitors; Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Gout; Non-alcoholic steatohepatitis

Most Recent Events

  • 28 Aug 2022 No recent reports of development identified for preclinical development in Gout in USA
  • 28 Nov 2021 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA
  • 17 Jan 2019 Acquist Therapeutics has patent protection for compounds intended for treatment of patients with NASH, gout, and other illnesses in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top